CN118766834A - 用于金刚烷类药物缓释的胃驻留系统 - Google Patents

用于金刚烷类药物缓释的胃驻留系统 Download PDF

Info

Publication number
CN118766834A
CN118766834A CN202410745376.9A CN202410745376A CN118766834A CN 118766834 A CN118766834 A CN 118766834A CN 202410745376 A CN202410745376 A CN 202410745376A CN 118766834 A CN118766834 A CN 118766834A
Authority
CN
China
Prior art keywords
gastric
adamantane
drug
polymer
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410745376.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·贝林格
R·卡纳斯蒂
J·H·杨
B·卡特
S·扎勒
N·比海斯
S·洛
J·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lindera Treatment Co
Original Assignee
Lindera Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindera Treatment Co filed Critical Lindera Treatment Co
Publication of CN118766834A publication Critical patent/CN118766834A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410745376.9A 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统 Pending CN118766834A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662402947P 2016-09-30 2016-09-30
US62/402,947 2016-09-30
US201762490466P 2017-04-26 2017-04-26
US62/490,466 2017-04-26
US201762517718P 2017-06-09 2017-06-09
US62/517,718 2017-06-09
PCT/US2017/054608 WO2018064630A1 (en) 2016-09-30 2017-09-29 Gastric residence systems for sustained delivery of adamantane-class drugs
CN201780074281.7A CN110022861B (zh) 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780074281.7A Division CN110022861B (zh) 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统

Publications (1)

Publication Number Publication Date
CN118766834A true CN118766834A (zh) 2024-10-15

Family

ID=61760251

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410745376.9A Pending CN118766834A (zh) 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统
CN201780074281.7A Active CN110022861B (zh) 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780074281.7A Active CN110022861B (zh) 2016-09-30 2017-09-29 用于金刚烷类药物缓释的胃驻留系统

Country Status (7)

Country Link
US (1) US11576866B2 (enExample)
EP (1) EP3518902A4 (enExample)
JP (2) JP2019532947A (enExample)
CN (2) CN118766834A (enExample)
AU (1) AU2017336154B2 (enExample)
CA (1) CA3038557A1 (enExample)
WO (1) WO2018064630A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016016406A (es) 2014-06-11 2017-10-12 Massachusetts Inst Technology Estructuras de permanencia, y métodos relacionados.
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
TWI811221B (zh) 2017-06-09 2023-08-11 美商萊恩卓治療公司 具有釋放速率調節膜之胃的滯留系統
WO2019071087A1 (en) * 2017-10-06 2019-04-11 DigiM Solution LLC SYSTEM AND METHOD FOR CALCULATING PERFORMANCE OF CONTROLLED RELEASE OF MEDICINE USING IMAGES
CA3118056A1 (en) * 2018-08-15 2020-02-20 Lyndra, Inc. Systems for enteric delivery of therapeutic agents
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
CN113840596A (zh) 2019-03-20 2021-12-24 林德拉治疗公司 用于胃滞留剂型的衣层
IL286512B2 (en) * 2019-03-20 2026-03-01 Lyndra Therapeutics Inc Capsules and capsule coatings for stomach-retaining dosage forms
EP4054538A4 (en) * 2019-11-08 2024-02-07 Lyndra Therapeutics, Inc. STOMACH RESIDENCE SYSTEMS WITH A FILAMENT FOR IMPROVED STOMACH RESIDENCE
WO2021092486A1 (en) * 2019-11-08 2021-05-14 Lyndra, Inc. Formulations for release-rate modulating films for gastric residence systems
CA3160665A1 (en) * 2019-11-08 2021-05-14 Lyndra Therapeutics, Inc. Gastric residence systems for administration of active agents
IL292848A (en) * 2019-11-08 2022-07-01 Lyndra Therapeutics Inc Polymeric links for the gastric retention system
EP4121017A4 (en) * 2020-03-17 2024-07-03 Blaesi, Aron H. EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR EXTENDED ACTIVE INGREDIENT RELEASE
CN116234540A (zh) 2020-07-29 2023-06-06 赛康特集团有限责任公司 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留
JP2024503485A (ja) * 2021-01-19 2024-01-25 リンドラ セラピューティクス， インコーポレイティド リスペリドンを投与するための胃内滞留システム
AU2022270208A1 (en) * 2021-05-05 2023-12-07 Lyndra Therapeutics, Inc. Gastric residence systems comprising methadone
EP4333823A4 (en) * 2021-05-05 2025-04-09 Lyndra Therapeutics, Inc. Indwelling gastric sytems containing buprenorphine and naloxone
IL314378A (en) * 2022-01-19 2024-09-01 Lyndra Therapeutics Inc Dosage forms for gastric preservation
WO2024249946A2 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1957564A (en) 1932-11-23 1934-05-08 Aubra T West Expanding capsule body
US3154461A (en) 1960-03-07 1964-10-27 Minnesota Mining & Mfg Matte-finish polymeric film and method of forming the same
US3531368A (en) 1966-01-07 1970-09-29 Toray Industries Synthetic filaments and the like
US3716614A (en) 1969-05-12 1973-02-13 Toray Industries Process of manufacturing collagen fiber-like synthetic superfine filament bundles
AU449029B2 (en) 1969-08-28 1974-04-17 Commonwealth Scientific And Industrial Research Organisation Device for administration to ruminants
JPS5512411B2 (enExample) 1974-03-12 1980-04-02
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4676507A (en) 1985-05-06 1987-06-30 Patterson Bruce D Puzzles forming platonic solids
US4735804A (en) * 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
DE3680024D1 (de) 1985-05-10 1991-08-08 Merck & Co Inc Abgabesystem fuer arzneimittel, das waehrend einer kontrollierten zeitspanne im magen zurueckgehalten werden kann.
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
EP0253554A3 (en) 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
CA1314742C (en) 1986-12-12 1993-03-23 Hiromu Terada Optical fiber array
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ228382A (en) 1989-03-17 1992-08-26 Carter Holt Harvey Plastic Pro Drug administering coil-like device for insertion in body cavity of animal
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
NZ234227A (en) 1989-06-30 1991-08-27 Smithkline Beecham Corp Delayed release dosage form
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US5047464A (en) 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5121329A (en) 1989-10-30 1992-06-09 Stratasys, Inc. Apparatus and method for creating three-dimensional objects
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5939467A (en) 1992-06-26 1999-08-17 The Procter & Gamble Company Biodegradable polymeric compositions and products thereof
US5369142A (en) 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
WO1995003558A1 (en) 1993-07-19 1995-02-02 Reflexite Corporation Retroreflective structure
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5837276A (en) 1994-09-02 1998-11-17 Delab Apparatus for the delivery of elongate solid drug compositions
US6962579B2 (en) 1995-03-23 2005-11-08 Advanced Animal Technology Limited Substance delivery device
DE69628344T2 (de) 1995-03-23 2004-04-01 Advanced Animal Technology Ltd. Vorrichtung zur Verabreichung einer Substanz
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU2521797A (en) 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP5178982B2 (ja) 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
WO2001091553A1 (en) 2000-05-26 2001-12-06 Demegen, Inc. Composite wafer for controlled drug delivery
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US6627206B2 (en) 2001-07-25 2003-09-30 Greg A. Lloyd Method and apparatus for treating obesity and for delivering time-released medicaments
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
JP2005501097A (ja) 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー 膨張可能な胃内滞留装置
US20050165136A1 (en) 2002-01-23 2005-07-28 Uab Research Foundation Glass-ionomer cements containing amino acids
US6960617B2 (en) 2002-04-22 2005-11-01 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10224352A1 (de) 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
MY142179A (en) 2002-07-25 2010-10-15 Glaxo Group Ltd Multicomponent pharmaceutical dosage form
CA2501345A1 (en) 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
WO2004073690A1 (en) 2003-02-19 2004-09-02 Mnemoscience Gmbh Self-expanding device for the gastrointestinal or urogenital area
JP4497833B2 (ja) 2003-04-21 2010-07-07 富士フイルム株式会社 ポジ型平版印刷版原版
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20070129784A1 (en) 2003-06-13 2007-06-07 Mnemoscience Gmbh Stents
WO2004112755A1 (en) 2003-06-18 2004-12-29 John Michael Newton Controlled release devices with lumens
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US8048169B2 (en) 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
DE10350556A1 (de) 2003-10-29 2005-06-02 Clariant Gmbh Wasserbasierende Pigmentpräparationen
US6825308B1 (en) 2003-10-29 2004-11-30 Council Of Scientific And Industrial Research Copolymers and preparation thereof
WO2005056708A2 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
EP1703898A2 (en) 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
TW200539903A (en) 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
DE102004047076A1 (de) 2004-09-28 2006-04-06 Zimmer Ag Verfahren zur Herstellung von Polyestern
IL166183A0 (en) 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
AU2006209239A1 (en) 2005-01-27 2006-08-03 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrophilic biocompatible adhesive formulations and uses
JP5175553B2 (ja) 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2006323082A (ja) 2005-05-18 2006-11-30 Canon Inc 現像剤補給容器
US8021384B2 (en) 2005-07-26 2011-09-20 Ram Weiss Extending intrabody capsule
JP4981671B2 (ja) 2005-08-05 2012-07-25 滋賀県 ポリマーブレンドを含んでなる液中物質捕集材料
US20070048383A1 (en) 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
EP1957052A2 (en) 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
US8187633B2 (en) 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
US7674396B2 (en) 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
DK2997953T3 (en) 2006-01-18 2019-04-15 Intec Pharma Ltd ADMINISTRATION ORAL ADMINISTRATION
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US20090246142A1 (en) 2006-03-10 2009-10-01 Massachusetts Institute Of Technology Triggered Self-Assembly of Nanoparticles In Vivo
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
KR20090065524A (ko) 2006-09-04 2009-06-22 파나세아 바이오테크 리미티드 프로그래머블 부력전달기술
US20080075766A1 (en) 2006-09-25 2008-03-27 Shun-Por Li Multi-core dosage form having transparent outer coating
CA2673511A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008140651A2 (en) 2007-03-13 2008-11-20 Olson Arthur J Self-assembled polyhedra
US20100297009A1 (en) 2007-03-13 2010-11-25 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
US20080249156A1 (en) 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US8481076B2 (en) 2007-05-25 2013-07-09 Gorham Enterprises Llc Bariatric magnetic apparatus and method of manufacturing thereof
US8038659B2 (en) 2007-10-17 2011-10-18 The Invention Science Fund I, Llc Disintegrating digestive tract interaction system
US8637455B2 (en) 2007-10-22 2014-01-28 Affinergy, Llc Compositions and methods for delivery of glycopeptide antibiotics to medical device surfaces
EP2262367A4 (en) 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20130273135A1 (en) 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
US9066877B2 (en) 2008-04-28 2015-06-30 Eat Little Inc. Bezoar-forming units for weight control
US20100256342A1 (en) 2008-08-12 2010-10-07 Francis Raymond Salemme Protein nodes for controlled nanoscale assembly
KR20110042366A (ko) 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
AU2009303347B2 (en) 2008-10-10 2013-10-24 Reva Medical, Inc. Expandable slide and lock stent
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
AU2009330716A1 (en) 2008-12-27 2011-08-18 Chandra S. Duggirala Devices for treating obesity and methods of using those devices
EP2401225B1 (en) 2009-02-26 2014-10-22 The Regents of The University of California A supramolecular approach for preparation of size controllable nanoparticles
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
DE102009028076A1 (de) 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US20110052700A1 (en) 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
WO2011032087A2 (en) 2009-09-11 2011-03-17 Replication Medical Inc. Swellable polymeric device for dietary regulation
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US9421169B2 (en) 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
CN101711752B (zh) 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
WO2011139796A2 (en) 2010-04-27 2011-11-10 The Johns Hopkins University Self-folding sub-centimeter structures
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
EP3711750B1 (en) 2010-08-05 2023-09-06 TARIS Biomedical LLC Implantable drug delivery devices for genitourinary sites
US20120165793A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165794A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
EP2764557A4 (en) 2011-09-26 2016-04-27 Univ Northeastern ADJUSTABLE EMBEDDED SENSORS
ES2603278T3 (es) 2011-12-09 2017-02-24 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
US8979887B2 (en) 2012-02-24 2015-03-17 Elwha Llc Devices, systems, and methods to control stomach volume
AU2013290875A1 (en) 2012-07-16 2015-02-05 APET Holding B.V. Gastro-retentive drug delivery system
US9307966B2 (en) 2012-08-15 2016-04-12 St. Jude Medical Puerto Rico Llc Vascular closure device anchor
ES2623176T3 (es) 2012-08-16 2017-07-10 Teva Pharmaceutical Industries Ltd. Composición farmacéutica de memantina
US10441760B2 (en) 2013-03-01 2019-10-15 The Johns Hopkins University Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
CN103654903A (zh) 2013-11-27 2014-03-26 西安交通大学 一种用于人体消化道吻合的磁性可降解装置
WO2015083171A1 (en) 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US20170051099A1 (en) 2014-04-29 2017-02-23 The Brigham And Women's Hospital, Inc. Polymeric materials for bio-applications
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US10485758B2 (en) 2014-06-02 2019-11-26 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
MX2016016406A (es) 2014-06-11 2017-10-12 Massachusetts Inst Technology Estructuras de permanencia, y métodos relacionados.
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
JP2018536007A (ja) 2015-12-01 2018-12-06 クレキシオ バイオサイエンシーズ エルティーディー． 胃保持性装置
JP2018537201A (ja) 2015-12-02 2018-12-20 クレキシオ バイオサイエンシーズ エルティーディー． 胃保持型投与形態を調整する装置および方法
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
US20200230244A1 (en) 2016-11-09 2020-07-23 Massachusetts Institute Of Technology Triggerable hydrogel compositions and related methods
ES2966736T3 (es) 2016-12-02 2024-04-24 Clexio Biosciences Ltd Sistema de residencia gástrica
TWI811221B (zh) 2017-06-09 2023-08-11 美商萊恩卓治療公司 具有釋放速率調節膜之胃的滯留系統
JP7288435B2 (ja) 2017-09-20 2023-06-07 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムのカプセル封入
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019232291A1 (en) 2018-05-31 2019-12-05 Massachusetts Institute Of Technology Drug delivery articles for gram-level dosing
WO2020102648A1 (en) 2018-11-15 2020-05-22 Massachusetts Institute Of Technology Millineedle systems for esophageal drug delivery

Also Published As

Publication number Publication date
CN110022861B (zh) 2024-06-28
EP3518902A4 (en) 2020-07-08
CA3038557A1 (en) 2018-04-05
JP2019532947A (ja) 2019-11-14
AU2017336154A1 (en) 2019-04-18
JP7565999B2 (ja) 2024-10-11
WO2018064630A1 (en) 2018-04-05
AU2017336154B2 (en) 2023-11-09
EP3518902A1 (en) 2019-08-07
US20190231697A1 (en) 2019-08-01
US11576866B2 (en) 2023-02-14
JP2023040036A (ja) 2023-03-22
CN110022861A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
JP7565999B2 (ja) アダマンタン系薬物の持続的送達のための胃内滞留システム
JP7588177B2 (ja) 放出速度調節フィルムを有する胃内滞留システム
AU2017268840B2 (en) Materials architecture for gastric residence systems
US11576859B2 (en) Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US20220409528A1 (en) Gastric residence systems having a filament for improved gastric residence
CN103874484B (zh) 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物
US20220387312A1 (en) Gastric residence systems having arms with controlled stiffness for improved gastric residence
KR20100017109A (ko) 지프라시돈 제제
US20240398701A1 (en) Manufacturing methods for gastric residence systems
EP3110403B1 (en) Taste masking drug formulations
US9107921B2 (en) Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Bülbül et al. Schizophrenia; a review on promising drug delivery systems
TWI837082B (zh) 用於胃滯留系統之材料架構
KR102046395B1 (ko) 베포타스틴 또는 이의 약제학적으로 허용 가능한 염을 포함하는 서방성 제제
Nagori et al. SUSTAINED RELEASE MATRIX DRUG DELIVERY SYSTEM: A
TW202500122A (zh) 用於胃滯留系統之材料架構

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination